These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1090 related items for PubMed ID: 26640956
1. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection. Macías J, López-Cortés LF, Téllez F, Recio E, Ojeda-Burgos G, Ríos MJ, Rivero-Juárez A, Delgado M, Rivas-Jeremías, Pineda JA. PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956 [Abstract] [Full Text] [Related]
2. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G. J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [Abstract] [Full Text] [Related]
3. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P, Italian Co-infection Study (ICOS) Group. Antivir Ther; 2005 Feb; 10(2):309-17. PubMed ID: 15865225 [Abstract] [Full Text] [Related]
4. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, Fernández-Carbia A, González-Lassalle E, Salgado-Mercado R, Marxuach-Cuétara AM. J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957 [Abstract] [Full Text] [Related]
5. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group. Clin Infect Dis; 2014 Dec 15; 59(12):1768-76. PubMed ID: 25139963 [Abstract] [Full Text] [Related]
6. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group. J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523 [Abstract] [Full Text] [Related]
7. Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Sulkowski MS, Fessel WJ, Lazzarin A, Berenguer J, Zakharova N, Cheinquer H, Côté P, Dieterich D, Gadano A, Matthews G, Molina JM, Moreno C, Pineda JA, Pulido F, Rivero A, Rockstroh J, Hernandez D, McPhee F, Eley T, Liu Z, Mendez P, Hughes E, Noviello S, Ackerman P. Hepatol Int; 2017 Mar 15; 11(2):188-198. PubMed ID: 28210927 [Abstract] [Full Text] [Related]
8. Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-Gonzalez E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, González-García J. J Antimicrob Chemother; 2016 Jan 15; 71(1):244-50. PubMed ID: 26483516 [Abstract] [Full Text] [Related]
9. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin. Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J. Arch Virol; 2013 Sep 15; 158(9):1907-15. PubMed ID: 23553458 [Abstract] [Full Text] [Related]
10. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L, Jessner W. Clin Infect Dis; 2014 Dec 01; 59(11):1579-87. PubMed ID: 25192745 [Abstract] [Full Text] [Related]
11. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M. Liver Int; 2015 Jan 01; 35(1):120-9. PubMed ID: 25041136 [Abstract] [Full Text] [Related]
12. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study. Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M. Antivir Ther; 2015 Jan 01; 20(1):39-48. PubMed ID: 24831457 [Abstract] [Full Text] [Related]
13. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Núnez M, Camino N, Ramos B, Berdún MA, Barreiro P, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Martín-Carbonero L, Romero M, García-Samaniego J, Soriano V. Antivir Ther; 2005 Jan 01; 10(5):657-62. PubMed ID: 16152759 [Abstract] [Full Text] [Related]
14. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients. Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA. Enferm Infecc Microbiol Clin; 2013 Jan 01; 31(7):424-9. PubMed ID: 23453582 [Abstract] [Full Text] [Related]
15. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM, FIPSE LT-HIV Investigators. J Hepatol; 2015 Jan 01; 62(1):92-100. PubMed ID: 25127748 [Abstract] [Full Text] [Related]
16. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients. Mira JA, Valera-Bestard B, Arizcorreta-Yarza A, González-Serrano M, Torre-Cisneros J, Santos I, Vergara S, Gutiérrez-Valencia A, Girón-González JA, Macías J, López-Cortés LF, Pineda JA. Antivir Ther; 2007 Jan 01; 12(4):523-9. PubMed ID: 17668561 [Abstract] [Full Text] [Related]
17. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? Gonçales FL, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS. BMC Infect Dis; 2010 Jul 20; 10():212. PubMed ID: 20646277 [Abstract] [Full Text] [Related]
18. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, Bonet L, Vidal F, Milinkovic A, Bassa A, Villalonga C, Pérez I, Tural C, Martínez-Rebollar M, Calvo M, Blanco JL, Martínez E, Sánchez-Tapias JM, Gatell JM, Mallolas J. Hepatology; 2009 Jan 20; 49(1):22-31. PubMed ID: 19085908 [Abstract] [Full Text] [Related]
19. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group. Antivir Ther; 2007 Jan 20; 12(4):469-76. PubMed ID: 17668555 [Abstract] [Full Text] [Related]
20. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3. Vigani AG, Gonçales ES, Pavan MH, Genari F, Tozzo R, Lazarini MS, Fais V, Feltrin A, Gonçales NS, Gonçales FL. Braz J Infect Dis; 2012 Jan 20; 16(3):232-6. PubMed ID: 22729189 [Abstract] [Full Text] [Related] Page: [Next] [New Search]